Search by Categories
- Insights
- Rare Disease
- Oncology
- Cell and Gene Therapy
- Medical Devices
- Consulting
- News & Analysis
-
Therapeutic Areas
Our expertise in the industry
From Science Fiction to Reality: Investigating the Market Dynamics and Growing Demand for the Smart Pills
Over the past few years, the evolution of Smart Pills has been remarkable, driven largely by advancements in technology and innovative developments in healthcare. These pills, equipped with sensors, microprocessors, and wireless communication capabilities, have revolutionized the field of medicine. Technological innovations such as miniaturization, improved battery life, and enhanced data processing capabilities have allowed Smart Pills to become more efficient and accessible. Additionally, the Smart Pills market is addressing unmet needs in healthcare, particularly in the realms of diagnostics and patient monitoring. These pills offer a non-invasive and convenient…
Ipsen and Skyhawk Therapeutics Partnership; SynOx Therapeutics’ Phase III Trial; Roche’s Alecensa FDA Approval; AbbVie’s RINVOQ Phase III SELECT-GCA Trial; AskBio’s AB-1002 FDA Fast Track Designation
Ipsen Partners with Skyhawk Therapeutics for RNA-Focused Research in Rare Neurological Disorders Ipsen and Skyhawk Therapeutics have entered into an exclusive global partnership to explore and create new small molecules that can influence RNA for rare neurological conditions. Under this agreement, Ipsen has the option to obtain exclusive rights worldwide for developing promising candidates resulting from the collaboration. Once successful candidates are identified, Ipsen will oversee all subsequent activities. Skyhawk's innovative platform expedites the development of small molecules targeting RNA in various therapeutic domains, particularly focusing on rare neurological disorders.…
Empowering Change: REZDIFFRA’s Trailblazing Journey in NASH Treatment
Liver disease emerges as a burgeoning global health concern, presenting a myriad of formidable challenges. From viral hepatitis to alcoholic liver disease, nonalcoholic fatty liver disease (NAFLD), liver cirrhosis, and hepatocellular carcinoma (HCC), these conditions collectively afflict millions, exacting a toll of morbidity, mortality, and economic burden. Within this landscape, NAFLD/nonalcoholic steatohepatitis (NASH) recently renamed MASH (metabolic dysfunction-associated steatohepatitis) assumes prominence as a pivotal contributor. NAFLD, a comprehensive term encapsulating a spectrum of liver afflictions, encompasses everything from benign steatosis to progressive hepatocellular injury accompanied by fibrosis, cirrhosis, and, in…